Potential antibiotic resistant pathogens in community-acquired pneumonia: playing it safe is anything but

Since the introduction of the concept of healthcare-associated pneumonia (HCAP) in the 2005 update on the treatment of nosocomial pneumonias by the American Thoracic Society and the Infectious Diseases Society of America [1], there has been considerable controversy over whether this new category has been helpful or harmful. The core of the problem is the tension between clinicians perceiving that missing a methicillin-resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa may have dire consequences for their patient and the goals of antibiotic stewardship in reducing the use of too broad spectrum antibiotics driving patient-specific side effects like renal toxicity, Clostridium difficile or vancomycin-resistant enterocoli [2] infection, and the more generalised harm through the promotion of antibiotic-resistant bacteria within the hospital environment.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Editorials Source Type: research

Related Links:

The Food and Drug Administration approved Nabriva Therapeutics' drug application for its antibiotic Xenleta. Xenleta treats community-acquired bacterial pneumonia (CABP), a leading cause of infection-related deaths in the United States. Nabriva's stock was up 20% at $2.67 per share in after-hours trading Monday. According to the company, about 5 million cases of pneumonia are reported in the United Sta tes each year, and pneumonia is the fifth-leading cause of hospitalizations. Nabriva said Xenleta…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
The new semisynthetic pleuromutilin antibiotic will be available for oral and IV administration with a short 5- to 7-day course of therapy for community-acquired bacterial pneumonia (CABP).FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Infectious Diseases News Alert Source Type: news
The FDA approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
Nabriva Therapeutics Plc on Monday priced an oral and injectable version of its antibiotic Xenleta, which treats community-acquired pneumonia, at more than $200 per day after it received approval from the U.S. Food and Drug Administration.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Conditions:   Mechanical Ventilation Complication;   Ventilator Associated Pneumonia;   Nursing Caries;   Aspiration, Respiratory Interventions:   Device: Smart Cuff Manager;   Device: Manometer Sponsors:   Afyonkarahisar University of Health Sciences;   The Scientific and Technological Research Council of Turkey;   Afyonkarahisar Health Sciences University Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(Natural News) Bacteria do not need animal or human carriers to spread. A Rutgers-led study suggests that microbes take advantage of natural air currents and use them as bridges to travel from one remote location to another. The genes that encode antibiotic resistance in bacteria appear in many seemingly unrelated bacterial species. Even microbes separated by thousands of...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
Publication date: Available online 17 August 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Alexandra Leonard, Jingya Wang, Li Yu, Hao Liu, Yeriel Estrada, Lydia Greenlees, Roderick McPhee, Alexey Ruzin, Emma Guttman-Yassky, Michael D. HowellAbstractBackgroundAtopic dermatitis (AD) is a chronic inflammatory disease with significant local and systemic inflammation and barrier disruption. AD is associated with increased risk of allergen sensitization and skin colonization by Staphylococcus aureus. The heterogeneity of AD is unknown, and its complexity suggests its subdivision into several e...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
ConclusionHospital ownership was not found to have a major influence on the incidence of HCAI in Germany.
Source: Journal of Hospital Infection - Category: Infectious Diseases Source Type: research
The World Health Organization is issuing a warning about a group of deadly bacteria: Recently, the WHO released its first-ever list of “priority pathogens,” a list of antibiotic-resistant bacteria that the organization says pose the greatest threat to human health. The list is divided into three categories: critical-, high- and medium-priority. Three pathogens made it into the critical-priority group. These bacteria are resistant to multiple antibiotics and pose a high risk to people in hospitals and nursing homes, the WHO says. Multidrug-resistant bacteria, sometimes called “superbugs,” are a ...
Source: Science - The Huffington Post - Category: Science Source Type: news
New antibiotics need to be developed urgently to combat 12 families of bacteria, the World Health Organization said on Monday, describing these “priority pathogens” as the greatest threats to human health. The United National health agency said many of these bacteria have already evolved into deadly superbugs that are resistant to many antibiotics. The bugs “have built-in abilities to find new ways to resist treatment” the WHO said, and can also pass on genetic material that allows other bacteria to become drug-resistant. Governments need to invest in research and development (R&D)if new drugs are t...
Source: Healthy Living - The Huffington Post - Category: Consumer Health News Source Type: news
More News: Clostridium Difficile | Environmental Health | Hospitals | Infectious Diseases | MRSA | Pneumonia | Respiratory Medicine | Staphylococcus Aureus | Superbugs | Toxicology